PHMB Stock Overview
Focuses on operating a network of companion animal cancer treatment centers in the United States. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PharmaCom BioVet, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.000001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | 0% |
3 Year Change | -99.00% |
5 Year Change | -99.00% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
PHMB | US Healthcare | US Market | |
---|---|---|---|
7D | 0% | 0.7% | -0.2% |
1Y | 0% | -10.7% | 25.8% |
Return vs Industry: PHMB exceeded the US Healthcare industry which returned -10.7% over the past year.
Return vs Market: PHMB underperformed the US Market which returned 25.8% over the past year.
Price Volatility
PHMB volatility | |
---|---|
PHMB Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 7.6% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 18.6% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHMB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PHMB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | n/a | n/a | n/a |
PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States. The company focuses on developing bone marrow transplantation and other cancer treatment procedures to benefit companion animals that are diagnosed with lymphoma, other different types of cancers, and other diseases that are incurable. It has licensed a series of proprietary devices and compounds that would reduce suffering in animals with cancer.
PharmaCom BioVet, Inc. Fundamentals Summary
PHMB fundamental statistics | |
---|---|
Market cap | US$10.78k |
Earnings (TTM) | US$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs PHMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHMB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$0 |
Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did PHMB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/05 07:44 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | N/A |
Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmaCom BioVet, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|